Alarcón-Segovia D, Sanchez-Guerrero J
Department of Immunology and Rheumatology, Instituto Nacional de la Nutrición Salvàdor Zubirán, México City, México.
J Rheumatol. 1989 Apr;16(4):482-8.
An antiphospholipid antibody (APLA) syndrome has been proposed for those patients with systemic lupus erythematosus (SLE) or with other connective tissue diseases who have APLA and manifestations that seem related to their effect (venous thrombosis, arterial occlusions, thrombocytopenia, hemolytic anemia, recurrent fetal loss, leg ulcers, and livedo reticularis). Occurrence of a primary antiphospholipid syndrome has also been mentioned but not defined. We present 9 young patients who had at least 2 of the clinical manifestations that have been related to high titers of APLA, but had neither SLE nor other recognizable connective tissue disease. We propose criteria for diagnosis of such a primary antiphospholipid syndrome and discuss the possible mechanisms whereby a single autoantibody can cause systemic disease.
对于那些患有系统性红斑狼疮(SLE)或其他结缔组织疾病且伴有抗磷脂抗体(APLA)以及与其作用相关表现(静脉血栓形成、动脉闭塞、血小板减少、溶血性贫血、反复流产、腿部溃疡和网状青斑)的患者,有人提出了抗磷脂抗体综合征。也有人提到了原发性抗磷脂综合征的发生,但未给出定义。我们报告了9例年轻患者,他们至少有2种与高滴度APLA相关的临床表现,但既没有SLE也没有其他可识别的结缔组织疾病。我们提出了诊断这种原发性抗磷脂综合征的标准,并讨论了单一自身抗体可导致全身性疾病的可能机制。